세계의 EV 기반 액체 생검 시장 : 바이오마커 유형별, 샘플 유형별, 용도별, 최종 사용자별, 국가별, 지역별 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

EV-Based Liquid Biopsy Market size was valued at US$ 355.23 Million in 2024, expanding at a CAGR of 19.5% from 2025 to 2032.

The EV-based liquid biopsy market focuses on the use of extracellular vehicles (EVs) as a non-invasive diagnostic tool. EVs are nano-sized particles naturally released by cells into bodily fluids such as blood, saliva, and urine. These vesicles carry biological information, like RNA, DNA, proteins, and lipids, that reflects the state of their originating cells. This makes them valuable for detecting and monitoring diseases, especially cancers. Unlike traditional biopsies, EV-based liquid biopsies reduce patient discomfort and enable real-time tracking of disease progression. They are also advantageous for detecting tumors that are difficult to access or monitor using conventional methods.

Growing interest in precision medicine, early disease detection, and less invasive diagnostics is driving the adoption of this technology. Additionally, EVs are more stable in circulation compared to other biomarkers, which enhances their reliability. The market is expanding due to ongoing research, improved isolation techniques, and broader clinical applications. Despite some challenges, including a lack of standardization and regulatory clarity, EV-based liquid biopsy is emerging as a promising tool in modern diagnostics.

EV-Based Liquid Biopsy Market- Market Dynamics

Rising hospital-acquired infection control protocols drive demand for needle destroyers.

A key niche driver for the EV-based liquid biopsy market is the growing demand for non-invasive cancer monitoring using extracellular vesicle (EV) biomarkers. Traditional cancer diagnostics often rely on invasive tissue biopsies, which can be painful, risky, and not always feasible, especially for tumors in inaccessible locations. EVs, released by cancer cells into body fluids, carry genetic and proteomic information that mirrors the tumor's state. This enables clinicians to track cancer progression, therapeutic response, or recurrence with simple fluid samples like blood.

The ability to perform serial sampling offers real-time monitoring without subjecting patients to repeated invasive procedures. Additionally, EVs are more stable in circulation than other biomarkers like cell-free DNA, improving result reliability. As oncology shifts toward personalized and precision-based approaches, EV-based biopsies are becoming a valuable tool for tailoring treatments. Their role is particularly significant in cases where tissue biopsy is not possible due to the patient's health or tumor location. This rising clinical demand continues to propel innovation and investment in EV-based diagnostics.

EV-Based Liquid Biopsy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.5% over the forecast period (2025-2032)

Based on Biomarker Type segmentation, microRNA (miRNA) and messenger RNA (mRNA), were predicted to show maximum market share in the year 2024

Based on Sample Type segmentation, Blood was the leading Sample Type in 2024

Based on Application segmentation, Cancer diagnostics was the leading Application in 2024

Based on region, North America was the leading revenue generator in 2024

EV-Based Liquid Biopsy Market- Segmentation Analysis:

The Global EV-Based Liquid Biopsy Market is segmented based on Biomarker Type, Sample Type, Application, End-user, and Region.

The market is divided into four categories based on Biomarker Type. Proteins, RNA (miRNA, mRNA, etc.), DNA, Lipids, Others. Among the biomarker types in the EV-based liquid biopsy market, RNA, including microRNA (miRNA) and messenger RNA (mRNA), emerges as the most dominant segment. This prominence is due to the critical role RNA plays in reflecting the genetic activity of originating cells, especially cancer cells. EVs carry stable RNA molecules that provide valuable insights into gene expression patterns, enabling early disease detection and monitoring.

Compared to other biomolecules, RNA biomarkers offer high specificity and sensitivity, which are essential for accurate diagnosis and prognosis. miRNAs, in particular, regulate various cellular processes and have been linked to tumor progression, making them powerful indicators in liquid biopsies. Additionally, advances in RNA sequencing and analysis technologies have improved the ability to detect and quantify EV-associated RNAs reliably. The growing focus on personalized medicine further supports the use of RNA biomarkers, as they help tailor treatments based on molecular profiles. Despite challenges in isolating pure RNA from EVs, ongoing research is overcoming these obstacles, cementing RNA's position as a key driver in this market.

The market is divided into five categories based on Application: Cancer Diagnostics, Infectious Diseases, Neurological Disorders, Cardiovascular Diseases, and Others. Cancer diagnostics is the most dominant Sample Type segment in the EV-based liquid biopsy market. This dominance stems from the critical need for early, accurate, and minimally invasive methods to detect and monitor cancer. Extracellular vesicles released by tumor cells carry molecular signatures such as proteins, RNA, and DNA that provide real-time information about tumor presence, progression, and response to treatment. Unlike traditional tissue biopsies, EV-based liquid biopsies allow for continuous monitoring through simple blood or body fluid samples, reducing patient discomfort and enabling earlier intervention.

The rising global cancer burden and increasing emphasis on personalized medicine have further driven the adoption of EV-based diagnostics in oncology. Additionally, these liquid biopsies help detect tumors that are difficult to access or monitor through conventional methods. Research and clinical trials continue to validate the efficacy of EV biomarkers in cancer detection, making this Sample Type the primary growth driver for the market. While other Sample Types like infectious diseases and neurological disorders are emerging, cancer diagnostics currently remain the focal point of EV-based liquid biopsy development and commercialization.

EV-Based Liquid Biopsy Market- Geographical Insights

In North America, the EV-based liquid biopsy market is experiencing strong momentum due to advanced healthcare infrastructure and early adoption of innovative diagnostic technologies. The region benefits from a robust research ecosystem supported by academic institutions, biotech companies, and government funding initiatives focused on cancer diagnostics. There is a growing awareness among healthcare professionals about the clinical value of extracellular vesicles in non-invasive disease detection and monitoring. The integration of EV-based tests into clinical practice is facilitated by the presence of well-established regulatory frameworks and ongoing clinical trials.

The United States is at the forefront of the EV-based liquid biopsy market, driven by its advanced healthcare infrastructure and strong emphasis on early cancer detection. The country's robust research ecosystem, encompassing leading academic institutions and bioEnd-user firms, fosters continuous innovation in diagnostic technologies. A growing preference for non-invasive diagnostic methods among clinicians and patients has accelerated the adoption of EV-based liquid biopsies, which offer real-time insights into disease progression and treatment response. The U.S. Food and Drug Administration (FDA) plays a pivotal role in regulating these emerging technologies, ensuring safety and efficacy standards are met. However, challenges persist, including the need for standardized protocols for EV isolation and analysis.

EV-Based Liquid Biopsy Market- Competitive Landscape:

The competitive landscape of the EV-based liquid biopsy market is shaped by a mix of established bioend-user firms and innovative startups focused on extracellular vesicle technologies. Companies such as Exosome Diagnostics, Thermo Fisher Scientific, and Qiagen are prominent players, leveraging their strong research capabilities and global reach to advance EV-based diagnostics. Bio-Techne Corporation and NanoView Biosciences are also making significant strides through technological innovations in EV detection and characterization. Meanwhile, System Biosciences (SBI), Miltenyi Biotec, and AMSBIO are contributing specialized EV isolation and analysis kits.

Emerging companies like Exosomics S.p.A, Codiak BioSciences, and VivaZome Therapeutics are intensifying competition by developing novel EV-based platforms tailored for oncology and personalized medicine. The market is highly dynamic, with strategic collaborations, research partnerships, and clinical validations playing a key role in shaping competitive positioning. As regulatory pathways become clearer, these companies are expected to expand their presence in clinical settings.

Recent Developments:

In October 2024, QIAGEN expanded its automated liquid biopsy portfolio to enhance oncology, prenatal care, and organ transplant applications. The new ccfDNA Kit upgrade with a urine protocol for EZ1 and 2 instruments is designed to improve liquid biopsy workflows for cancer research. The QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for downstream applications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL EV-BASED LIQUID BIOPSY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• Exosome Diagnostics
• Bio-Techne Corporation
• Thermo Fisher Scientific
• NanoView Biosciences
• System Biosciences (SBI)
• Qiagen
• Norgen Biotek Corp.
• BioVision Inc.
• Miltenyi Biotec
• Creative Biolabs
• AMSBIO
• Exosomics S.p.A
• NX Pharmagen
• VivaZome Therapeutics
• Aethlon Medical
• Evox Therapeutics
• Capricor Therapeutics
• Codiak BioSciences
• Anjarium Biosciences
• HansaBioMed Life Sciences

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2019 - 2032

• Proteins
• RNA (miRNA, mRNA, etc.)
• DNA
• Lipids
• Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

• Blood
• Urine
• Saliva
• Cerebrospinal Fluid
• Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

• Cancer Diagnostics
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Diseases
• Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

• Hospitals & Clinics
• Research Institutes
• Diagnostic Laboratories
• Biopharmaceutical Companies
• Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. EV-Based Liquid Biopsy Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. EV-Based Liquid Biopsy Market Snippet by Biomarker Type
  • 2.1.2. EV-Based Liquid Biopsy Market Snippet by Sample Type
  • 2.1.3. EV-Based Liquid Biopsy Market Snippet by Application
  • 2.1.4. EV-Based Liquid Biopsy Market Snippet by End-user
  • 2.1.5. EV-Based Liquid Biopsy Market Snippet by Country
  • 2.1.6. EV-Based Liquid Biopsy Market Snippet by Region
• 2.2. Competitive Insights

3. EV-Based Liquid Biopsy Key Market Trends

• 3.1. EV-Based Liquid Biopsy Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. EV-Based Liquid Biopsy Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. EV-Based Liquid Biopsy Market Opportunities
• 3.4. EV-Based Liquid Biopsy Market Future Trends

4. EV-Based Liquid Biopsy Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. EV-Based Liquid Biopsy Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. EV-Based Liquid Biopsy Market Landscape

• 6.1. EV-Based Liquid Biopsy Market Share Analysis, 2024
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. EV-Based Liquid Biopsy Market - By Biomarker Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Biomarker Type, 2024 & 2032 (%)
  • 7.1.2. Proteins
  • 7.1.3. RNA (miRNA, mRNA, etc.)
  • 7.1.4. DNA
  • 7.1.5. Lipids
  • 7.1.6. Others

8. EV-Based Liquid Biopsy Market - By Sample Type

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
  • 8.1.2. Blood
  • 8.1.3. Urine
  • 8.1.4. Saliva
  • 8.1.5. Cerebrospinal Fluid
  • 8.1.6. Others

9. EV-Based Liquid Biopsy Market - By Application

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
  • 9.1.2. Cancer Diagnostics
  • 9.1.3. Infectious Diseases
  • 9.1.4. Neurological Disorders
  • 9.1.5. Cardiovascular Diseases
  • 9.1.6. Others

10. EV-Based Liquid Biopsy Market - By End-user

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
  • 10.1.2. Hospitals & Clinics
  • 10.1.3. Research Institutes
  • 10.1.4. Diagnostic Laboratories
  • 10.1.5. Biopharmaceutical Companies
  • 10.1.6. Others

11. EV-Based Liquid Biopsy Market- By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. EV-Based Liquid Biopsy Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. EV-Based Liquid Biopsy Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3.9. UK
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.9.3. UK Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.9.4. UK Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.9.6. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3.10. France
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.10.3. France Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.10.4. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.10.6. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3.11. Italy
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.11.3. Italy Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.11.4. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.11.6. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3.12. Spain
    • 11.3.12.1. Overview
    • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.12.3. Spain Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.12.4. Spain Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.12.6. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3.13. The Netherlands
    • 11.3.13.1. Overview
    • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.13.3. The Netherlands Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.13.4. The Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.13.6. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Overview
    • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.14.6. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3.15. Russia
    • 11.3.15.1. Overview
    • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.15.3. Russia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.15.4. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.15.6. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3.16. Poland
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.16.3. Poland Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.16.4. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.16.6. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3.17. Rest of Europe
    • 11.3.17.1. Overview
    • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. EV-Based Liquid Biopsy Key Manufacturers in Asia Pacific
  • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.4.4. APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  • 11.4.5. APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  • 11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.4.7. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4.8. China
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.8.3. China Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.8.4. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.8.6. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4.9. India
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.9.3. India Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.9.4. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.9.6. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4.13. Indonesia
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.13.3. Indonesia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.13.4. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.13.6. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4.14. Thailand
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.14.3. Thailand Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.14.4. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.14.6. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4.16. Rest of APAC
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.4.16.3. Rest of APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.4.16.4. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
• 11.5. Latin America (LATAM)
  • 11.5.1. Overview
  • 11.5.2. EV-Based Liquid Biopsy Key Manufacturers in Latin America
  • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.5.4. LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  • 11.5.5. LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  • 11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.5.7. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
• 11.6. Middle East and Africa (MEA)
  • 11.6.1. Overview
  • 11.6.2. EV-Based Liquid Biopsy Key Manufacturers in Middle East and Africa
  • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 11.6.4. MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  • 11.6.5. MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  • 11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.6.7. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6.14. Rest of MEA
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 11.6.14.3. Rest of MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
    • 11.6.14.4. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- EV-Based Liquid Biopsy Industry

• 12.1. Competitive Dashboard
  • 12.1.1. Competitive Benchmarking
  • 12.1.2. Competitive Positioning
• 12.2. Company Profiles
  • 12.2.1. Exosome Diagnostics
  • 12.2.2. Bio-Techne Corporation
  • 12.2.3. Thermo Fisher Scientific
  • 12.2.4. NanoView Biosciences
  • 12.2.5. System Biosciences (SBI)
  • 12.2.6. Qiagen
  • 12.2.7. Norgen Biotek Corp.
  • 12.2.8. BioVision Inc.
  • 12.2.9. Miltenyi Biotec
  • 12.2.10. Creative Biolabs
  • 12.2.11. AMSBIO
  • 12.2.12. Exosomics S.p.A
  • 12.2.13. NX Pharmagen
  • 12.2.14. VivaZome Therapeutics
  • 12.2.15. Aethlon Medical
  • 12.2.16. Evox Therapeutics
  • 12.2.17. Capricor Therapeutics
  • 12.2.18. Codiak BioSciences
  • 12.2.19. Anjarium Biosciences
  • 12.2.20. HansaBioMed Life Sciences

13. 360 Degree AnalystView

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us